中国实用眼科杂志
中國實用眼科雜誌
중국실용안과잡지
CHINESE JOURNAL OF PRACTICAL OPHTHALMOLOGY
2011年
4期
319-321
,共3页
前列腺素%青光眼%角膜厚度%基质金属蛋白酶
前列腺素%青光眼%角膜厚度%基質金屬蛋白酶
전렬선소%청광안%각막후도%기질금속단백매
Prostamide%Prostaglandin analogs%Glaucoma%Central corneal thickness%Matrix metalloproteinase
目的 观察局部使用前列腺素类药物后中央角膜厚度的改变.方法 回顾性病例临床对照研究.对2009年1～12月在潍坊医学院临床学院眼科就诊的40例70只眼原发性开角型青光眼病人,随机分为两组,其中前列腺素组21例36只眼,噻吗心安组19例34只眼,在用药前分别测量两组的中央角膜厚度,随后按照给定的方法用药,用药随访时间为8周±7d,用药后再测量中央角膜厚度.采用配对资料的t检验进行统计分析.结果 用药前拉坦前列腺素组病人中央角膜厚度平均为(0.545±0.035)mm,曲伏前列腺素组为(0.544±0.026)mm,噻吗心安组为(0.536±0.045)mm,前列腺素组与噻吗心安组相比差异无统计学意义(P＞0.05);用药后拉坦前列腺素组平均中央角膜厚度为(0.496±0.034)mm,曲伏前列腺素组为(0.502±0.030)mm,较用药前中央角膜厚度明显降低,差异具有统计学意义(P＜0.01),用药后噻吗心安组中央角膜厚度为(0.542±0.036)mm,较用药前相比变化不大,差异无统计学意义(P＞0.05).结论 局部使用前列腺素类药物后可以改变角膜基质细胞的细胞外基质,使中央角膜厚度变薄,其主要是通过调节基质金属蛋白酶来实现的.在临床实践中,局部使用前列腺素类药物治疗时,角膜变薄会造成用压平眼压计测量时低估眼压水平.
目的 觀察跼部使用前列腺素類藥物後中央角膜厚度的改變.方法 迴顧性病例臨床對照研究.對2009年1～12月在濰坊醫學院臨床學院眼科就診的40例70隻眼原髮性開角型青光眼病人,隨機分為兩組,其中前列腺素組21例36隻眼,噻嗎心安組19例34隻眼,在用藥前分彆測量兩組的中央角膜厚度,隨後按照給定的方法用藥,用藥隨訪時間為8週±7d,用藥後再測量中央角膜厚度.採用配對資料的t檢驗進行統計分析.結果 用藥前拉坦前列腺素組病人中央角膜厚度平均為(0.545±0.035)mm,麯伏前列腺素組為(0.544±0.026)mm,噻嗎心安組為(0.536±0.045)mm,前列腺素組與噻嗎心安組相比差異無統計學意義(P＞0.05);用藥後拉坦前列腺素組平均中央角膜厚度為(0.496±0.034)mm,麯伏前列腺素組為(0.502±0.030)mm,較用藥前中央角膜厚度明顯降低,差異具有統計學意義(P＜0.01),用藥後噻嗎心安組中央角膜厚度為(0.542±0.036)mm,較用藥前相比變化不大,差異無統計學意義(P＞0.05).結論 跼部使用前列腺素類藥物後可以改變角膜基質細胞的細胞外基質,使中央角膜厚度變薄,其主要是通過調節基質金屬蛋白酶來實現的.在臨床實踐中,跼部使用前列腺素類藥物治療時,角膜變薄會造成用壓平眼壓計測量時低估眼壓水平.
목적 관찰국부사용전렬선소류약물후중앙각막후도적개변.방법 회고성병례림상대조연구.대2009년1～12월재유방의학원림상학원안과취진적40례70지안원발성개각형청광안병인,수궤분위량조,기중전렬선소조21례36지안,새마심안조19례34지안,재용약전분별측량량조적중앙각막후도,수후안조급정적방법용약,용약수방시간위8주±7d,용약후재측량중앙각막후도.채용배대자료적t검험진행통계분석.결과 용약전랍탄전렬선소조병인중앙각막후도평균위(0.545±0.035)mm,곡복전렬선소조위(0.544±0.026)mm,새마심안조위(0.536±0.045)mm,전렬선소조여새마심안조상비차이무통계학의의(P＞0.05);용약후랍탄전렬선소조평균중앙각막후도위(0.496±0.034)mm,곡복전렬선소조위(0.502±0.030)mm,교용약전중앙각막후도명현강저,차이구유통계학의의(P＜0.01),용약후새마심안조중앙각막후도위(0.542±0.036)mm,교용약전상비변화불대,차이무통계학의의(P＞0.05).결론 국부사용전렬선소류약물후가이개변각막기질세포적세포외기질,사중앙각막후도변박,기주요시통과조절기질금속단백매래실현적.재림상실천중,국부사용전렬선소류약물치료시,각막변박회조성용압평안압계측량시저고안압수평.
Objective To determine ifglaucoma treatment with topically administered prostamide or prostaglandin analogs could change central corneal thickness (CCT). Methods Of 40 patients (70 eyes) were divided into two groups, 21 patients (36 eyes) treated with prostamide, 19 patients (34 eyes) with timolol. CCT was measured by ultrasound pachometry. The data of glaucomatous patients who had their CCT measured before and after monotherapy treatment were analyzed retrospectively. Follow-up time was 8 weeks ± 7 days.Paired test was used for statistical analysis. Results Initial mean± SD CCT was (0.544± 0.035 )mm. After 8 weeks± 7 days, mean± SD CCT was (0.539± 0.036 )mm. This reduction on CCT was statistically significant (P ＜0.001). Conclusions Central corneal thickness measured by means of ultrasound pachometry decreases during treatment with topically administered prostamide or prostaglandin analogs.
